Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3FXYD2
The experimentally established mechanism targets of Digoxin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 14/20 | 0.91 |
| ▸ | ATP1B1 known ✓ | P05026 | 14/20 | 0.91 |
| ▸ | ATP1B2 known ✓ | P14415 | 14/20 | 0.91 |
| ▸ | ATP1A2 known ✓ | P50993 | 14/20 | 0.91 |
| ▸ | ATP1B3 known ✓ | P54709 | 14/20 | 0.91 |
| ▸ | ATP1A3 known ✓ | P13637 | 4/20 | 0.91 |
| ▸ | FXYD2 known ✓ | P54710 | 4/20 | 0.91 |
| ▸ | ATP1A4 known ✓ | Q13733 | 4/20 | 0.91 |
| ▸ | TP53 | P04637 | 4/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.91 |
| ▸ | NPC1 | O15118 | 2/20 | 0.91 |
| ▸ | STAT3 | P40763 | 2/20 | 0.91 |
| ▸ | RAB9A | P51151 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | GLA | P06280 | 1/20 | 0.91 |
| ▸ | RECQL | P46063 | 1/20 | 0.91 |
| ▸ | RORC | P51449 | 1/20 | 0.91 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.91 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Digitoxin SCHEMBL16859871 | 0.97 | ATP1A1 (0.86) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL8367956 | 0.97 | ATP1A1 (0.86) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL8200838 | 0.95 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL12841137 | 0.95 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digitoxin SCHEMBL2321116 | 0.95 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digitoxin SCHEMBL17862021 | 0.95 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digitoxin SCHEMBL20582729 | 0.95 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digitoxin SCHEMBL20970016 | 0.95 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL22904197 | 0.95 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL13337586 | 0.95 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007037788-A1 | ANTIBODY COMPOSITION AND PASSIVE IMMUNIZATION AGAINST PREGNANCY-INDUCED HYPERTENSION USING ANTIDIGOXIN ANTIBODY (DIGIBIND) | ADAIR CHARLES DAVID (US) | 2007-04-05 | — | — | WO | claimed |
| US-20060134106-A1 | Antibody composition and passive immunization against pregnancy-induced hypertension | VELO BIO, LLC | 2006-06-22 | — | — | US | claimed |
| US-20140234410-A1 | COMBINATION PRODUCTS | SIGMOID PHARMA LTD. (IE) | 2014-08-21 | — | — | US | disclosed |
| EP-2322146-B1 | Microcapsule formulations comprising two pharmaceutically active ingredients | SIGMOID PHARMA LTD (IE) | 2012-12-12 | — | — | EP | disclosed |
| EP-2444071-A1 | Minicapsule formulations | Sigmoid Pharma Limited (IE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2322146-A2 | Microcapsule formulations comprising two pharmaceutically active ingredients | Sigmoid Pharma Limited (IE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2156826-A1 | Microcapsule formulations comprising two pharmaceutically active ingredients | Sigmoid Pharma Limited (IE) | 2010-02-24 | — | — | EP | disclosed |
| EP-2153824-A1 | Seamless multiparticulate formulations | Sigmoid Pharma Limited (IE) | 2010-02-17 | — | — | EP | disclosed |
| US-20080113031-A1 | seamless capsules having cores containing drugs, to enhance bioavailability, sustained release or time release of drugs | SIGMOID PHARMA LIMITED (IE) | 2008-05-15 | — | — | US | disclosed |
| US-20080020018-A1 | Combination Products | SIGMOID PHARMA LIMITED (IE) | 2008-01-24 | — | — | US | disclosed |
| EP-1811979-A2 | MICROCAPSULES COMPRISING A METHYLXANTHINE AND A CORTICOSTEROID | Sigmoid Biotechnologies Limited (IE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1499303-A4 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | MILLER FRED H (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1802287-A2 | MINICAPSULE FORMULATIONS | Sigmoid Biotechnologies Limited (IE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006035418-A2 | MICROCAPSULES COMPRISING A METHYLXANTHINE AND A CORTICOSTEROID | SIGMOID BIOTECHNOLOGIES LIMITED (IE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035416-A2 | MINICAPSULE FORMULATIONS | SIGMOID BIOTECHNOLOGIES LIMITED (IE) | 2006-04-06 | — | — | WO | disclosed |
| EP-1499303-A2 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | Miller, Fred H. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003086267-A2 | MULTI-PHASE, MULTI-COMPARTMENT CAPSULAR SYSTEM | MILLER FRED H (US) | 2003-10-23 | — | — | WO | disclosed |
| US-5837289-A | ORGANOGEL COMPRISING FATTY ACID PHOSPHOLIPID EMULSIFYING AGENT AND FATTY ACID OR ESTER THEREOF | IMPRIMIS PHARMACEUTICALS, INC. | 1998-11-17 | — | — | US | disclosed |
| EP-0013262-B1 | A PHARMACEUTICAL PREPARATION COMPRISING A CARDIAC GLYCOSIDE WITH A POLYMER COATING, AND A PROCESS FOR PREPARATION THEREOF | Aktiebolaget Hässle (SE) | 1983-08-03 | — | — | EP | disclosed |
| WO-1981000113-A1 | IMMOBILIZED CATALYSTS HAVING THEIR ORIGIN IN HIGHER PLANTS | BRODELIUS P (SE) | 1981-01-22 | — | — | WO | disclosed |